I posted a few times long ago w/SUPG, and have had shares for about 1.5 years now. I have an honest question to ask for all who will give an real answer (no flaming, please).
I read the news that ASTX pulled the plug on Amuvatinib. Pre-market the share price is down $.30-ish. Here's my question: was 10% of ASTX's value yesterday built on a continuation for the Amuvatinib testing? It seems to me that the response to the news is something of a knee-jerk, especially since Amuvatinib was years away from even earning any revenues.
No chance. Everyone who followed this stock knew this was the least "valuable" of the 4 Phase 2 drugs. Their updates on this drug were still based on a patient that had a good reaction to the drug 3/4 years ago. He has since passed away.